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Introduction

28
When treating locally advanced Non-Small Cell Lung Cancer (NSCLC) patients, 29 proton therapy may spare Organs-At-Risk (OARs) significantly better than photon ther- The purpose of this study is to evaluate the separate and combined effects of respira-50 tion and interfractional anatomical changes during the course of treatment on the dose 51 delivery in spot scanning proton therapy using daily Cone-Beam CT (CBCT) scans.
52
These scans capture daily variations as well as progressive anatomical changes.
53
Method and materials
54
Patient selection 55 In our clinic, about 5% of NSCLC patients are treated to a lower dose than the stan-56 dard 66Gy (24×2.75Gy) Intensity Modulated Radiotherapy (IMRT) prescription due to 57 normal tissue constraints, mainly high mean lung dose. With proton therapy, these pa-58 tients might be treated to the intended dose while meeting normal tissue constraints.
59
Therefore we have selected retrospectively and consecutively sixteen of these stage 60 IIIA/B patients (Table S1) 
Treatment planning
63
Spot-scanning proton plans were created using the Pinnacle 3 research version 9.100
64
Treatment Planning System (TPS) with a prescription dose of 66GyE (relative biolog-and (2) using a single field uniformity tolerance (amount of deviation from unifor-76 mity tolerated as a percentage of the target dose) of 3% (labeled Single Field Uniform 77 Dose (SFUD)). For both, a weighted scenario-based robustness tool [7, 8] to the biologically equivalent dose before summation.
111
To estimate the effects of realistic anatomical variations on the delivered dose, the 112 accumulated dose distribution over the entire treatment course of five weeks was com-113 pared with the planned dose distribution for both IMPT and SFUD plans.
114
Target coverage was evaluated using the difference in the minimum dose to 99%
115
of the volume ∆D 99 (α/β = 10GyE) between the planned dose and recalculated dose.
116
We have set a difference ≤2GyE to be acceptable. Although any threshold is somewhat 117 arbitrary, 2GyE equals the standard dose of one fraction dose, and thus represents a 
124
The time between the pCT and the first treatment day can be up to two weeks.
125
To distinguish early and late changes, and to evaluate the effects of shorter treatment 126 schedules, we accumulated the recalculated dose also over the first week and first two 127 weeks of the treatment.
128
Three dose evaluation methods were analyzed: (1) only respiratory motion,
129 only day-to-day anatomy variations and (3) day-to-day anatomy variation combined 130 with respiratory motion (summarized in Figure A2 ). Note that only regular respiration 131 is evaluated given the amplitudes reported in Table S1 . Our plans were optimized to be robust against respiratory motion and day-to-day
153
variation. 
Results
167
Data from sixteen patients (Table S1) is the first study published on this topic using 4DCT and daily CBCTs.
193
During the course of treatment, anatomical changes should not lead to unacceptable 194 underdosage of the targets or an unacceptable overdosage of the OARs. The IGTV con-
195
cept applied here leads to plans that are fairly robust against respiratory motion alone.
196
We observed a much larger effect on the accumulated dose due to day-to-day varia- dose variations in the targets will be larger when atelectasis changes along the path of 208 the proton beams. Considering that robust planning will not be able to cope with such 209 large density variations, adaptive planning is required in these cases.
210
The patients selected for this study were treated with IMRT to a lower dose than 211 our standard of 66Gy due to OAR constraints. Proton plans of 66GyE on the other 212 hand, met all OAR dose constraints but were susceptible to anatomical changes. As
213
IMRT plans are typically more robust against anatomical changes, it is currently un-214 clear which patients would have benefited from proton therapy over photon therapy.
215
Our results show that adaptive radiotherapy and/or advanced planning strategies ca- tasis occurs/disappears, and the tissue-to-tissue correspondence will not be possible.
264
Due to this, the dose differences in patients with large differences in the amount of at-265 electasis might be underestimated, since the difference between the mCT and the pCT 266 will be smaller than it actually is. In the extreme case, such as for Patient 3, the atelec-267 tasis was totally resolved from the first CBCT, while it was largely present in the pCT.
268
The mCTs deviate visibly from the CBCTs and were therefore not representative of where the lung density changes during breathing. On the other hand, by using the pCT 276 to create the mCTs, we excluded potential effects of contrast in the analyses.
277
Another assumption is that the tumor shrinkage is elastic paper. Figure A1 shows the scans of patient A. 
449
Robust treatment planning
450
The TPS utilized a weighted scenario-based robustness tool as described earlier.
451
This robust optimization was performed using default settings of the TPS, where the 452 scenarios were weighted as follows: 25% for range, 25% for setup in 3 directions and we calculated the ratio of this volume of these plans (Table S3) :
This ratio indicates which plan achieved a robust plan with less high dose volume using Table S3 ). The HI is defined dose than the IMPT beams, with p < 0.001 (t-test).
494 Table S1 : Patient characteristics, including stage, volume of the primary tumor, volume of the total involved lymph nodes, number of involved lymph nodes (LN), peakto-peak amplitude of the primary tumor, days between the CT scan (t CT ) and first treatment day (t 1 ), number of available CBCTs of each patient, and the intra-thoracic anatomical changes (ITACs) over course of treatment [15] . The ITACs are classified in four color codes: red (dangerous), orange (risky), yellow (cautious) and green (safe).
Note that this classification was developed for photons and would be different in the context of protons. The primary tumor of Patient 5 was not visible anymore after induction chemotherapy and was therefore not treated. In this particular case, the peak-to-peak amplitude was derived from two lymph nodes. Patient A is included for the dose error estimation due to the registration error. The values in the parentheses are the values found for the repeat CT. Figure A1 : The four scans of Patient A: planning CT (A), repeat CT (B), CBCT (D) and mCT (E). And overlays of scans for better visualization: planning CT (purple) and repeat CT (green) (C), mCT (purple) and CBCT (green) (F), planning CT (purple) and CBCT (green) (G), repeat CT (purple) and mCT (green) (H), and repeat CT (purple) and CBCT (green) (I) Figure A2 : Summary of the three different evaluation methods to evaluate the effects of respiratory and anatomical variations: only respiratory motion (4D MidP-CT), daily anatomy variations without respiratory motion (mMidP-CT) and daily anatomy variations including respiratory motion (4D mMidP-CT). 4D-DVF represents the deformation vector field mapping each phase of the 4D CT to its mid-position (MidP). 3D-DVF deforms the planning CT to the daily anatomy of the CBCT. TPS is the optimization in the treatment planning system, whereas "dose calc" refers to dose recalculation in the same system. The isocenter of the beams were shifted from the nominal plan in three directions or a range correction was applied. For each plan of a patient, only one case is shown, i.e. worst target (either GTV or GTV LN ) and worst direction (a shift or range correction). The isocenter was shifted from 3mm to 11mm, while only a range correction of ±3% was applied. 
